218 related articles for article (PubMed ID: 34089720)
1. Jak-STAT Inhibition Mediates Romidepsin and Mechlorethamine Synergism in Cutaneous T-Cell Lymphoma.
Cortes JR; Patrone CC; Quinn SA; Gu Y; Sanchez-Martin M; Mackey A; Cooke AJ; Shih BB; Laurent AP; Trager MH; Ferrando AA; Geskin LJ; Palomero T
J Invest Dermatol; 2021 Dec; 141(12):2908-2920.e7. PubMed ID: 34089720
[TBL] [Abstract][Full Text] [Related]
2. Romidepsin Plus Liposomal Doxorubicin Is Safe and Effective in Patients with Relapsed or Refractory T-Cell Lymphoma: Results of a Phase I Dose-Escalation Study.
Vu K; Wu CH; Yang CY; Zhan A; Cavallone E; Berry W; Heeter P; Pincus L; Wieduwilt MJ; William BM; Andreadis C; Kaplan LK; McCormick F; Porcu P; Brammer JE; Ai WZ
Clin Cancer Res; 2020 Mar; 26(5):1000-1008. PubMed ID: 31772119
[TBL] [Abstract][Full Text] [Related]
3. Romidepsin and Afatinib Abrogate Jak-Signal Transducer and Activator of Transcription Signaling and Elicit Synergistic Antitumor Effects in Cutaneous T-Cell Lymphoma.
Shih BB; Ma C; Cortes JR; Reglero C; Miller H; Quinn SA; Albero R; Laurent AP; Mackey A; Ferrando AA; Geskin L; Palomero T
J Invest Dermatol; 2024 Jan; ():. PubMed ID: 38219917
[TBL] [Abstract][Full Text] [Related]
4. Kinome profiling analysis identified Src pathway as a novel therapeutic target in combination with histone deacetylase inhibitors for cutaneous T-cell lymphoma.
Jimura N; Fujii K; Qiao Z; Tsuchiya R; Yoshimatsu Y; Kondo T; Kanekura T
J Dermatol Sci; 2021 Mar; 101(3):194-201. PubMed ID: 33531202
[TBL] [Abstract][Full Text] [Related]
5. MAPK pathway activation leads to Bim loss and histone deacetylase inhibitor resistance: rationale to combine romidepsin with an MEK inhibitor.
Chakraborty AR; Robey RW; Luchenko VL; Zhan Z; Piekarz RL; Gillet JP; Kossenkov AV; Wilkerson J; Showe LC; Gottesman MM; Collie NL; Bates SE
Blood; 2013 May; 121(20):4115-25. PubMed ID: 23532732
[TBL] [Abstract][Full Text] [Related]
6. Romidepsin and interferon gamma: a novel combination for refractory cutaneous T-cell lymphoma.
Samimi S; Morrissey K; Anshelevich S; Evans K; Gardner J; Musiek A; Vittorio C; Rook A; Kim E
J Am Acad Dermatol; 2013 Jan; 68(1):e5-6. PubMed ID: 23244387
[No Abstract] [Full Text] [Related]
7. Novel therapeutic combination demonstrates more than additive effects in cutaneous T-cell lymphoma.
Dulmage BO; Story SK; Falo LD; Geskin LJ
Leuk Lymphoma; 2015 Jul; 56(7):2225-7. PubMed ID: 25511681
[No Abstract] [Full Text] [Related]
8. Romidepsin and Azacitidine Synergize in their Epigenetic Modulatory Effects to Induce Apoptosis in CTCL.
Rozati S; Cheng PF; Widmer DS; Fujii K; Levesque MP; Dummer R
Clin Cancer Res; 2016 Apr; 22(8):2020-31. PubMed ID: 26660520
[TBL] [Abstract][Full Text] [Related]
9. Reactive Oxygen Species-Mediated Synergism of Fenretinide and Romidepsin in Preclinical Models of T-cell Lymphoid Malignancies.
Makena MR; Koneru B; Nguyen TH; Kang MH; Reynolds CP
Mol Cancer Ther; 2017 Apr; 16(4):649-661. PubMed ID: 28119491
[TBL] [Abstract][Full Text] [Related]
10. Relief of intractable pruritus with romidepsin in patients with cutaneous T-cell lymphoma: A series of four cases.
Poligone B; Rubio-Gonzalez B; Querfeld C
Dermatol Ther; 2019 Mar; 32(2):e12804. PubMed ID: 30549384
[TBL] [Abstract][Full Text] [Related]
11. Vorinostat interferes with the signaling transduction pathway of T-cell receptor and synergizes with phosphoinositide-3 kinase inhibitors in cutaneous T-cell lymphoma.
Wozniak MB; Villuendas R; Bischoff JR; Aparicio CB; Martínez Leal JF; de La Cueva P; Rodriguez ME; Herreros B; Martin-Perez D; Longo MI; Herrera M; Piris MA; Ortiz-Romero PL
Haematologica; 2010 Apr; 95(4):613-21. PubMed ID: 20133897
[TBL] [Abstract][Full Text] [Related]
12. Romidepsin for cutaneous T-cell lymphoma.
Prince HM; Dickinson M; Khot A
Future Oncol; 2013 Dec; 9(12):1819-27. PubMed ID: 24295412
[TBL] [Abstract][Full Text] [Related]
13. Cutaneous T-Cell Lymphoma PDX Drug Screening Platform Identifies Cooperation between Inhibitions of PI3Kα/δ and HDAC.
Wu CH; Yang CY; Wang L; Gao HX; Rakhshandehroo T; Afghani S; Pincus L; Balassanian R; Rubenstein J; Gill R; Bandyopadhyay S; McCormick F; Moasser M; Ai WZ
J Invest Dermatol; 2021 Feb; 141(2):364-373. PubMed ID: 32603749
[TBL] [Abstract][Full Text] [Related]
14. Low-dose electron beam radiation and romidepsin therapy for symptomatic cutaneous T-cell lymphoma lesions.
Akilov OE; Grant C; Frye R; Bates S; Piekarz R; Geskin LJ
Br J Dermatol; 2012 Jul; 167(1):194-7. PubMed ID: 22372971
[TBL] [Abstract][Full Text] [Related]
15. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma.
Whittaker SJ; Demierre MF; Kim EJ; Rook AH; Lerner A; Duvic M; Scarisbrick J; Reddy S; Robak T; Becker JC; Samtsov A; McCulloch W; Kim YH
J Clin Oncol; 2010 Oct; 28(29):4485-91. PubMed ID: 20697094
[TBL] [Abstract][Full Text] [Related]
16. Romidepsin: a guide to its clinical use in cutaneous T-cell lymphoma.
Lyseng-Williamson KA; Yang LP
Am J Clin Dermatol; 2012 Feb; 13(1):67-71. PubMed ID: 22066664
[TBL] [Abstract][Full Text] [Related]
17. A prospective study of cutaneous intolerance to topical mechlorethamine therapy in patients with cutaneous T-cell lymphomas. French Study Group of Cutaneous Lymphomas.
Estève E; Bagot M; Joly P; Souteyrand P; Beylot-Barry M; Vaillant L; Delaunay M; Avril MF; Laroche L; Grange F; Thomine E; Wechsler J
Arch Dermatol; 1999 Nov; 135(11):1349-53. PubMed ID: 10566833
[TBL] [Abstract][Full Text] [Related]
18. Responses to romidepsin in patients with cutaneous T-cell lymphoma and prior treatment with systemic chemotherapy.
Duvic M; Bates SE; Piekarz R; Eisch R; Kim YH; Lerner A; Robak T; Samtsov A; Becker JC; McCulloch W; Waksman J; Whittaker S
Leuk Lymphoma; 2018 Apr; 59(4):880-887. PubMed ID: 28853310
[TBL] [Abstract][Full Text] [Related]
19. Romidepsin treatment for relapsed or refractory peripheral and cutaneous T-cell lymphoma: Real-life data from a national multicenter observational study.
Shimony S; Horowitz N; Ribakovsky E; Rozovski U; Avigdor A; Zloto K; Berger T; Avivi I; Perry C; Abadi U; Raanani P; Gafter-Gvili A; Gurion R
Hematol Oncol; 2019 Dec; 37(5):569-577. PubMed ID: 31674027
[TBL] [Abstract][Full Text] [Related]
20. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma.
Piekarz RL; Frye R; Turner M; Wright JJ; Allen SL; Kirschbaum MH; Zain J; Prince HM; Leonard JP; Geskin LJ; Reeder C; Joske D; Figg WD; Gardner ER; Steinberg SM; Jaffe ES; Stetler-Stevenson M; Lade S; Fojo AT; Bates SE
J Clin Oncol; 2009 Nov; 27(32):5410-7. PubMed ID: 19826128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]